Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacogenetics of methotrexate in inflammatory bowel disease.

Pharmacogenetics and genomics - 1 Oct 2005

Herrlinger Klaus R, Cummings J R Fraser, Barnardo Martin C N M, Schwab Matthias, Ahmad Tariq, Jewell Derek P

Abstract excerpt

OBJECTIVES: Methotrexate (MTX) is an effective immunosuppressive treatment in inflammatory bowel disease (IBD) but its use is limited by unpredictable toxicity and efficacy. MTX metabolism is complex involving a number of enzymes. An individual's response to MTX may in part be genetically determined by functional genetic variation in genes encoding these enzymes. We report a pharmacogenetic evaluation of MTX...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Colitis, Ulcerative

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crohn Disease

Share to Maximum Tolerated Dose

Share to Methotrexate

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Pharmacogenetics

Share to Reduced Folate Carrier Protein

Source

Identifiers

PMID: 16141796
DOI: 10.1097/01.fpc.0000172242.19675.33

Genes

MTHFR
RFC1
GGH

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacogenetics of methotrexate in inflammatory bowel disease.PMID 16141796Read ↗

Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.Semantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenetics in inflammatory bowel diseaseSemantic proximity Read ↗

Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.Semantic proximity Read ↗

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.Semantic proximity Read ↗

The pharmacogenetics of methotrexateSemantic proximity Read ↗

Pharmacogenetics of Inflammatory Bowel DiseaseSemantic proximity Read ↗

Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexateSemantic proximity Read ↗

Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.Semantic proximity Read ↗

Influence of FPGS rs1544105 and GGH rs3758149 Gene Polymorphisms on Methotrexate Pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics of inflammatory bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.